MDNews - Lower Hudson/Bronx

September 2014

Issue link: https://viewer.e-digitaledition.com/i/371410

Contents of this Issue

Navigation

Page 16 of 23

breakdown are still under investigation, Mapstone says. "We didn't set out to find specific metabolites," he says. "We looked at about 4,600 metabolites and discovered that 10 lipids were signifi cantly altered in the plasma of cognitively normal older adults who would go on to develop the clinical symptoms of Alzheimer's disease. We believe that this 10-lipid phospholipid biomarker panel refl ects the breakdown of neural cell membranes in those individuals destined to develop advanced moderate cognitive impairment or Alzheimer's disease and may mark the transition between preclinical states where synaptic dysfunction and early neurodegeneration give rise to subtle cognitive changes." One interesting result wa s that the APOE4 gene, associated with the risk of developing Alzheimer's, did not have significant predictive weight in this research. Also, the test predicted clinical Alzheimer's, based on patients' performance on cognitive skills tests, rather than distinguishing among causes of impairment, such as vascular dementia versus Alzheimer's. Potential for New Therapies Mapstone notes that the test may assist in fi nding new Alzheimer's medi- cations. By including people with early Alzheimer's — who would previously have been undiagnosed — trials may identify medical treatments that could be administered in a timely fashion. AARP Bulletin reporting takes this cau- tiously positive view, noting that a simple blood test to screen for Alzheimer's is a long way from being widely available. The Bulletin quotes bioethicist Craig Klugman of DePaul University, who explains that by the time patients and physicians have to decide whether to screen, effective therapies may be available. Implications and Awareness But how will people react to learning, years in advance of noticeable symptoms, that they will likely develop Alzheimer's disease — especially if the news arrives before defi nitive medications are devel- oped? The screening raises questions about everything from patients arranging their fi nances to adding features to their residences that will enable them to live at home longer. Additionally, ethicists, health policy experts and other observers point out the reality that some people might not want to know dementia is in their future — and that among some who are screened, the results could prompt considerations of suicide. People who abhor the prospect of living with dementia would have an interval of lucidity in which to act, writes Dena S. Davis, JD, PhD, Presidential Endowed Chair and Professor of Religion Studies at Lehigh University, on The Hastings Center's Bioethics Forum. The blog's editors conclude cautiously: "The big advantages of the blood test over the other biomarker tests are that it is easy to use and minimally invasive. These advantages … increase the necessity for society to examine the ethical implications for [such tests] and develop guidelines for their responsible use." David Hilfi ker, MD, a family medi- cine physician who was diagnosed with Alzheimer's disease, only to see the diag- nosis changed about two years later to cognitive impairment of unknown etiology, has written extensively about medicine, ethics and society. After Dr. Hilfi ker's diagnosis, he began studying and writing about dementia. "I suspect most people who fear Alzheimer's disease are cognitively normal," he says. "Before I noticed my cognitive impairment, I would have felt the same way. When I realized I had the impairment, I didn't feel that way anymore. "I feel fairly strongly that it is a good idea for people to know as quickly as possible whether they have some form of dementia," he continues. "This is important because a number of other c a u s e s [a p a r t f r om A l z h ei mer's] are treatable." However, Dr. Hilfiker adds a few caveats. Physicians should be prepared to offer necessar y care for patients who may become demented, including referral to a neurologist. "Most of us [physicians] are afraid of Alzheimer's," he says. "We can't talk about it in a helpful way; we ignore it or pussyfoot around it. Alzheimer's is one of the most common diagnoses of old age. We need to become much more comfortable with it." ■ SPECIAL CLINICAL SECTION: SENIOR HEALTH M D N E W S . CO M ■ MD NEWS Lower Hudson/Bronx | 1 7

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - September 2014